Abstract
The existence of long-lasting cellular reservoirs of HIV-1 is one of the major hurdles in developing effective anti-retroviral therapies. These latently infected cells and tissues efficiently evade immune responses and remain dormant until activated, upon which they can generate a productive HIV-1 infection. This classic scenario of viral latency becomes even more difficult to study and model due to the extreme complexity of translating in vivo virus-cell interactions into a controlled in vitro system. The recent developments and constant improvements upon hematopoietic engraftment of human cells and tissues onto recipient immunocompromised murine scaffolds have made it possible to model complex human innate and adaptive immune responses in a small animal model. Specifically, HIV-1 infection has been successfully modeled in these humanized mice to mimic transmission, pathogenesis, host immune responses, and treatment. Here, we review the complexities surrounding modeling HIV-1 latency in vitro and in vivo and highlight the most recent humanized mouse models that support retroviral infection.
Keywords: HIV-1, latency, HAART, humanized mouse model, HIV INFECTIONS, HIV-1 LATENCY, Primary Cells, Transformed cell lines, Small Animal Models, Latent reservoirs
Current HIV Research
Title: Humanized Mouse Models of HIV-1 Latency
Volume: 9 Issue: 8
Author(s): Rachel V. Duyne, Aarthi Narayanan, Kylene K.-Hall, Mohammed Saifuddin, Leonard Shultz and Fatah Kashanchi
Affiliation:
Keywords: HIV-1, latency, HAART, humanized mouse model, HIV INFECTIONS, HIV-1 LATENCY, Primary Cells, Transformed cell lines, Small Animal Models, Latent reservoirs
Abstract: The existence of long-lasting cellular reservoirs of HIV-1 is one of the major hurdles in developing effective anti-retroviral therapies. These latently infected cells and tissues efficiently evade immune responses and remain dormant until activated, upon which they can generate a productive HIV-1 infection. This classic scenario of viral latency becomes even more difficult to study and model due to the extreme complexity of translating in vivo virus-cell interactions into a controlled in vitro system. The recent developments and constant improvements upon hematopoietic engraftment of human cells and tissues onto recipient immunocompromised murine scaffolds have made it possible to model complex human innate and adaptive immune responses in a small animal model. Specifically, HIV-1 infection has been successfully modeled in these humanized mice to mimic transmission, pathogenesis, host immune responses, and treatment. Here, we review the complexities surrounding modeling HIV-1 latency in vitro and in vivo and highlight the most recent humanized mouse models that support retroviral infection.
Export Options
About this article
Cite this article as:
V. Duyne Rachel, Narayanan Aarthi, K.-Hall Kylene, Saifuddin Mohammed, Shultz Leonard and Kashanchi Fatah, Humanized Mouse Models of HIV-1 Latency, Current HIV Research 2011; 9 (8) . https://dx.doi.org/10.2174/157016211798998781
DOI https://dx.doi.org/10.2174/157016211798998781 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection
Current Drug Targets Burkholderia mallei and Burkholderia pseudomallei: The Causative Micro-organisms of Glanders and Melioidosis
Recent Patents on Anti-Infective Drug Discovery Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Preliminary Anti-Coxsackie Activity of Novel 1-[4-(5,6-dimethyl(H)- 1H(2H)-benzotriazol-1(2)-yl)phenyl]-3-alkyl(aryl)ureas
Medicinal Chemistry Multiple Roles for Chemokines in the Pathogenesis of SIV Infection
Current HIV Research Predicting the Potential Public Health Impact of Disease-Modifying HIV Vaccines in South Africa: The Problem of Subtypes
Current Drug Targets - Infectious Disorders Superheated Water as Solvent in Microwave Assisted Organic Synthesis of Compounds of Valuable Pharmaceutical Interest
Current Organic Chemistry Developments in High-Yield System Expressed Vaccines and Immunotherapy
Recent Patents on Biotechnology Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Neuro-Immune-Endocrine Mechanisms During Septic Shock: Role For Nitric Oxide in Vasopressin and Oxytocin Release
Endocrine, Metabolic & Immune Disorders - Drug Targets Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research Protective Immunity in Humans: A Glimpse Provided by the Analysis of Herpesvirus-Specific T Cells in Health and Disease
Current Immunology Reviews (Discontinued) Viral Protein Functions Study by Affinity Modification
Mini-Reviews in Medicinal Chemistry Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy
Current Neuropharmacology Patent Selections
Recent Patents on DNA & Gene Sequences Novel Therapeutic Strategies for Dementia
CNS & Neurological Disorders - Drug Targets Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science Simultaneous HPLC Determination of Metronidazole and Spiramycin in Plasma and Brain of Mouse
Current Pharmaceutical Analysis Role of CD14 in Host Response to Infection
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents